Clinic of Nuclear Medicine, Johannes Gutenberg-University, Mainz, Germany; Supervisory Center for Medical Radiation Protection, Bundeswehr Medical Service Headquarters, Koblenz, Germany; Bundeswehr Institute for Preventive Medicine, Koblenz, Germany; Clinic of Nuclear Medicine, Bundeswehr Central Hospital, Koblenz, Germany.
Clinic of Nuclear Medicine, Bundeswehr Central Hospital, Koblenz, Germany.
Urology. 2019 Aug;130:1-12. doi: 10.1016/j.urology.2019.04.004. Epub 2019 Apr 12.
Prostate-specific membrane antigen (PSMA) is a transmembrane protein with significantly increased expression in the cells and metastases of prostate carcinoma (CaP). PSMA-expression correlates with higher serum levels of prostate-specific antigen (PSA) and a higher Gleason score (GS). This finding has led to the development of novel imaging modalities such as 68Ga-/18F-labeled PSMA positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI). This article reviews the literature pertaining to various new imaging technologies for the management of CaP. PSMA positron emission tomography/computed tomography appears to be an excellent diagnostic tool, that may drastically impact the management of a large number of patients with primary and recurrent CaP.
前列腺特异性膜抗原（PSMA）是一种跨膜蛋白，在前列腺癌（CaP）的细胞和转移灶中表达显著增加。PSMA 的表达与前列腺特异性抗原（PSA）血清水平升高和 Gleason 评分（GS）升高相关。这一发现导致了新型成像方式的发展，如 68Ga/18F 标记的 PSMA 正电子发射断层扫描/计算机断层扫描（PET/CT）和正电子发射断层扫描/磁共振成像（PET/MRI）。本文综述了有关 CaP 管理的各种新型成像技术的文献。PSMA 正电子发射断层扫描/计算机断层扫描似乎是一种极好的诊断工具，可能会极大地影响大量原发性和复发性 CaP 患者的治疗。
